NasdaqCM:CELCBiotechs
Celcuity (CELC) Is Up 15.9% After Positive Phase 3 Results and FDA Review – Has the Bull Case Changed?
Celcuity recently announced positive topline results from its phase 3 Victoria 1 study, FDA acceptance of its new drug application under an expedited review program, and the completion of offerings raising approximately $287 million to support commercialization plans.
These achievements mark significant milestones towards bringing Celcuity’s lead drug candidate to market and have strengthened the company’s financial position for potential future growth.
We’ll explore how clinical progress...